PALO ALTO, Calif., May 1 /PRNewswire-FirstCall/ -- Telik, Inc. announced that company management will provide a corporate overview at the Deutsche Bank 2006 Health Care Conference in Boston on May 2, 2006 at 9:00 a.m. Eastern time. A webcast of the presentation will be available via the Deutsche Bank website, www.corporate- ir.net/media_files/event/2006/May/DeutscheBankHealthcare/Agenda/050206.htm.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(R) (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non- small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com//
